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Highlights: 
 ICP0 is a viral E3 ubiquitin ligase that promotes HSV-1 infection. 
 ICP0 interacts with multiple component proteins of the ubiquitin pathway. 
 ICP0 disrupts multiple cellular processes activated in response to infection 
 ICP0 remodels the SUMO proteome to counteract host immune defences to 
infection. 
 ICP0 is an attractive drug target for the development of antiviral HSV-1 therapeutics. 
 
Abstract 
 
Herpes simplex virus 1 (HSV-1) hijacks ubiquitination machinery to modify the cellular 
proteome to create an environment permissive for virus replication. HSV-1 encodes its own 
RING-finger E3 ubiquitin (Ub) ligase, Infected Cell Protein 0 (ICP0), that directly interfaces 
with component proteins of the Ub pathway to inactivate host immune defences and cellular 
processes that restrict the progression of HSV-1 infection. Consequently, ICP0 plays a 
critical role in the infectious cycle of HSV-1 that is required to promote the efficient onset of 
lytic infection and productive reactivation of viral genomes from latency. This review will 
describe the current knowledge regarding the biochemical properties and known substrates 
of ICP0 during HSV-1 infection. We will highlight the gaps in the characterization of ICP0 
function and propose future areas of research required to understand fully the biological 
properties of this important HSV-1 regulatory protein. 
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Abbreviations: ATM, Ataxia Telangiectasia-Mutated; ATRX, Alpha Thalassemia/mental 
Retardation syndrome X-linked; CENP, CENtromere Protein; ChIP, Chromatin Immuno 
Precipitation; Daxx, Death domain Associated protein; ΔICP0, null mutant ICP0 from HSV-1; 
FHA, ForkHead Associated; HAUSP, Herpesvirus-Associated Ubiquitin-Specific Protease; 
HIRA, HIstone cell cycle Regulator defective homologue A; IFI16; IFN-γ Inducible protein 16; 
IFN, InterFeroN; IRF3, Interferon Regulatory Factor 3; MDC1, Mediator of DNA damage 
Checkpoint 1; MRE11, Meiotic Recombination 11 Homolog 1; NBS1, Nijmegen Breakage 
Syndrome 1 (Nibrin); NF-κB, Nuclear Factor Kappa B; NLS, nuclear localization Signal; 
PIAS, Protein Inhibitor of Activated STAT; PML-NBs, ProMyelocytic Leukaemia Nuclear 
Bodies; PTM, Post-Translational Modification; RING, Really Interesting New Gene; Sp100, 
Speckled 100 kDa; STAT, Signal Transducer and Activator of Transcription; STING, 
STimulator of IFN Genes; STUbL , SUMO-Targeted Ubiquitin Ligase; SUMO, Small Ubiquitin 
MOdifier;  vDNA, viral DNA; TERRA, TElomere Repeat-containing RNA; TPP1, TriPeptidyl 
Peptidase 1; TP53BP1, Tumor Protein P53 Binding Protein 1. 
Keywords: HSV-1; ICP0; ubiquitin; PML-NBs; chromatin; immunity. 
 
 
1. Why are herpesviruses important? 
Herpesviruses are ubiquitous viral pathogens that cause a variety of clinically important 
diseases on a global scale, ranging from mild skin sores and rashes to blindness, congenital 
birth defects, cancer, and encephalitis [1]. The reason for their prevalence and evolutionary 
success is attributable to their ability to enter into a latent state of infection that is maintained 
for the duration of the host’s lifespan. This latent reservoir of virus evades immune 
clearance, which can periodically reactivate leading to recurrent disease and transmission to 
new hosts. Thus, understanding the cellular processes that regulate lytic and latent infection 
is essential to managing and treating the clinical conditions they cause. Such studies also 
provide fundamental insight into the molecular mechanisms employed by viruses to evade 
host immune defences that influence the outcome of infection, offering new opportunities for 
therapeutic intervention. 
 
2. HSV-1 interacts with and hijacks the host ubiquitin machinery   
Like many viruses, herpesviruses hijack component proteins of the host ubiquitin (Ub) 
machinery to subvert cellular processes in order to establish a conducive environment for 
replication [2, 3]. During HSV-1 infection, these events are largely driven by ICP0, a RING-
finger E3 Ub ligase expressed from the outset of nuclear infection [4, 5]. While ICP0 is 
classified as a non-essential viral gene product [6-9], research has established ICP0 to play 
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an important role in modulating the intracellular environment to promote the successful onset 
of lytic infection and productive reactivation of viral genomes from latency [6-15]. Importantly, 
the requirement for ICP0 during HSV-1 infection is cell type dependent, with many 
carcinoma cell lines being permissive to HSV-1 ICP0 mutant infection relative to normal 
diploid cells [6, 8, 10, 16]. With respect to osteosarcoma (U2OS and SAOS) cells, 
permissivity correlates with a defect in the recruitment of key antiviral host factors to infecting 
vDNA from the outset of nuclear infection (discussed below; [8, 16]). Such differences 
highlight the restrictive nature of the intrinsic (pre-existing) proteome to the initiation of HSV-
1 replication under low MOI conditions that can vary between infected cells [17-19]. Thus, 
understanding the biochemical and biological properties of ICP0 provides valuable insight 
into host factors and cellular processes which influence the restriction of many viral 
pathogens. 
Ubiquitination of proteins occurs in a sequential cascade consisting of E1 (Ub 
activating, UBE1), E2 (Ub conjugating, UBE2), and E3 (Ub ligating) enzymes [20]. The Ub 
ligase activity of ICP0 is entirely attributable to its N-terminal C3HC4 Zn2+-binding RING-
finger (residues 116-156), a structural domain conserved between α-herpesvirus ICP0 
orthologues (Figure 1; [4, 21-25]). ICP0 interacts directly with UBE2D1-4 (UbcH5a-d) and 
UBE2E1-3 (UbcH6a-c) Ub conjugating enzymes (7 out of 37 known human UBE2 proteins 
[4, 26-28]) via amino acid (aa) residues located on loop-1, loop-2, and α-helix of its RING-
finger domain (Figure 1, Figure 2; [27]). ICP0 facilitates the transfer of Ub from charged 
UBE2 enzymes onto lysine (K) residues within target-substrate(s) with which it interacts [29]. 
As Ub contains seven K residues (K6, K11, K27, K29, K33, K48, and K63), anchored Ub 
molecules can be further ubiquitinated to form linear or branched poly-ubiquitin chains [30]. 
Proteins conjugated with K48-linked chains are generally considered to be preferential 
substrates for proteasomal degradation [31-33]. UBE2D1-4 and UBE2E1-3 conjugating 
enzymes are highly conserved among Eukaryotes and known to support the K48-linked 
poly-ubiquitination of a wide range of substrates [28]. Accordingly, α-herpesvirus ICP0 family 
members have been shown to share similar biochemical properties in the presence of these 
UBE2 enzymes [23]. However, non-primate orthologues fail to complement fully the 
replication defect of an HSV-1 ICP0 mutant, indicative of species-specific mechanisms of 
Ub ligase substrate targeting ([22, 23]; reviewed in [34]). Importantly, mutation of ICP0-UBE2 
interaction residues inactivate ICP0 function [24, 25, 27], highlighting the importance of 
these host interactions in the biological lifecycle of HSV-1. As such, ICP0 represents an 
attractive drug target for the development of antiviral HSV-1 therapeutics [24, 35, 36]. It 
remains to be determined if ICP0 can interact with other UBE2 enzymes that may facilitate 
the differential ubiquitination of substrates or formation of alternative chain types, for 
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example N-terminal methionine-linked (Met1-linked) or K63-linked poly-ubiquitin chains [37, 
38]. ICP0 can also interact with a variety of cellular E3 Ub ligases, including RNF8, RNF168, 
SIAH1, and TRIM27 (Figure 3) [39-42]. It remains to be examined if these interactions can 
influence the biochemical properties of ICP0 or extend its repertoire of substrates 
independently of their respective degradation (discussed below; Figure 3). 
Ubiquitinated substrates can be recognized by deubiquitinase (DUB) enzymes, which 
cleave Ub chains from substrates [43]. ICP0 can induce its own autoubiquitination leading to 
its proteasomal degradation [4, 27, 44]. ICP0 counteracts this process by recruiting USP7 
(previously known as HAUSP [45, 46]; Figure 2), which cleaves anchored Ub chains from 
ICP0 leading to its stabilization [44, 47]. Reciprocally, ICP0 can ubiquitinate USP7 leading to 
its proteasomal degradation in an ICP0 phosphorylation-dependent manner [48, 49]. Recent 
structural studies have solved the interaction interface between ICP0 and USP7 which has 
been proposed as a potential drug target [50, 51]. It remains to be established whether 
ICP0’s interaction with USP7 can lead to the stabilization of other ICP0 interaction partners 
or influence Ub chain editing to promote substrate degradation. ICP0 can also interact with 
USP9X [52], although the biochemical relationship between these two proteins remains to be 
investigated. The HSV-1 deubiquitinase enzyme UL36 has also been reported to influence 
ICP0 expression levels during infection [53, 54], although it remains to be determined if 
UL36 can catalyse the deubiquitination of ICP0 directly. Collectively, these observations 
demonstrate ICP0 to interact with multiple component enzymes of the Ub pathway to 
promote a conducive environment favourable to HSV-1 replication.  
 
3. ICP0-mediated degradation of PML-NBs and SUMOylated host proteins  
ICP0 was initially identified as an E3 Ub ligase by virtue of its ability to localize to and disrupt 
PML-NBs [29, 55-59]. PML-NBs are highly dynamic nuclear substructures composed of 
more than 70 proteins that respond to a variety of stimuli, including heat shock, cytokine 
signalling, and virus infection [60-65]. Infecting HSV-1 genomes are rapidly entrapped by 
PML-NBs upon nuclear entry [16, 66], a host response that can lead to viral genome 
silencing as a component of the intrinsic antiviral immune response (discussed below) [16, 
67-70]. PML, the main scaffolding protein of PML-NBs [71], and Sp100 were among the first 
substrates identified to be degraded by ICP0 in a RING-finger dependent manner (Figure 3) 
[58, 72]. Consequently, the biological role of PML-NBs during virus infection has been 
extensively studied, which has revealed these discrete nuclear substructures to play an 
important function in the spatiotemporal regulation of host immune defences to virus 
infection [16, 73, 74]. 
The post-translational modification of proteins with SUMO plays a key role in the 
assembly of PML-NBs via a network of protein-protein interactions mediated between 
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constitutively SUMOylated proteins (e.g. PML and Sp100) and resident proteins that contain 
SUMO Interaction Motifs (SIMs) [71, 75-78]. Inhibiting cellular ubiquitination enriches SUMO-
modified transcription factors and DNA repair proteins at PML-NBs [79], highlighting the 
dynamic composition of PML-NBs. ICP0 contains seven SIM-Like Sequences (SLSs; Figure 
2) and shares biochemical properties similar to that of cellular SUMO Targeted Ubiquitin 
Ligases (STUbLs) [58, 59, 80-83]. ICP0 utilizes a combination of SUMO-dependent and -
independent targeting strategies to ubiquitinate and degrade PML isoforms I-VI and Sp100 
leading to the disruption of PML-NBs and release of viral genomes entrapped therein [16, 
72, 80-82, 84]. Of note, the structure of ICP0 SLS4 (residues 362-367; Figure 2) and SUMO 
has recently been solved by NMR [85], revealing cooperation between ICP0 phosphorylation 
domains (FHA [67-pTELF-70] and Phos2; Figure 2) in the degradation of SUMOylated 
proteins [49, 85, 86]. Importantly, this mechanism of SUMO targeting is not limited to PML-
NBs, as ICP0 has been shown to induce the degradation of numerous (≥ 120) SUMOylated 
proteins including ARID3A/E2FBP1, BEND3, ETV6, MBD1, NACC1, NACC2, ZBTB4, 
ZBTB10, ZBTB38, and MORC3 (Figure 3) [58, 59, 81, 83]. Degradation of MORC3 by ICP0 
has been proposed to inhibit the recruitment of PML-NB host factors to infecting viral 
genomes [87], an observation that warrants further investigation due to the importance of 
PML-NBs in the intracellular restriction of viral pathogens [74, 88]. In most cases, however, it 
remains to be determined if the degradation of these SUMOylated proteins is functionally 
relevant to HSV-1 infection or a consequence of collateral damage by the targeting 
mechanism employed by ICP0 to disrupt PML-NBs. Notably, it is becoming clear that PML-
NB host factors cooperate with host SUMOylation machinery (e.g. PIAS SUMO E3 ligases) 
to restrict HSV-1 infection [81, 89, 90]. Depletion of PIAS1 and PIAS4 in combination with 
PML significantly alleviates the restriction of an HSV-1 ICP0 mutant relative to PML 
depletion alone [89, 90]. Thus, ICP0’s ability to disrupt SUMO-SIM interactions through 
multiple targeting mechanisms is likely to be a common strategy employed by ICP0 to 
remodel proteome interaction networks that facilitate or maintain the intracellular restriction 
of HSV-1 [91-93]. 
 
4. Interplay between ICP0, chromatin remodelling, and intrinsic immunity 
HSV-1 genomes are delivered to the nucleus of newly infected cells as linear molecules of 
naked DNA [94], which immediately bind constitutively expressed host factors with pro- and 
antiviral cellular functions [95]. ChIP experiments have demonstrated infecting viral genomes 
to rapidly associate with cellular histones, which can carry distinct epigenetic signatures that 
influence the progression of viral transcription [70, 96-101]. Relevant to ICP0, microscopy 
experiments have shown the histone H3.3 chaperone complex Daxx/ATRX and IFI16 to 
associate with infecting HSV-1 genomes prior to vDNA entrapment within PML-NBs [16, 70, 
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102, 103], known repositories of non-nucleosomal histone H3.3 [104-107]. The recruitment 
of these host factors correlates with the epigenetic modification of histone H3 (H3K9me3 and 
H3K27me3) on viral chromatin which can lead to transcriptional silencing in the absence of 
ICP0 [70, 107, 108]. HSV-1 mutants that fail to express ICP0, or carry mutations that abolish 
its Ub ligase activity, have a significantly lower probability of initiating a productive infection 
in restrictive cell types (approximately 1000-fold relative to WT HSV-1; [10]). Such 
observations have led to the hypothesis that PML-NBs may act as an axis for vDNA 
chromatinization and gene silencing [107, 109], as vDNA remains stably entrapped in PML-
NBs in the absence of ICP0 under low MOI conditions [16, 107, 110, 111]. In support of this, 
resident PML-NB proteins (PML, Daxx and ATRX) have been shown to act cooperatively 
with IFI16 to restrict HSV-1 ICP0 gene expression that correlates with repressive histone 
signatures (H3K9me3 and H3K27me3) on viral chromatin [68-70, 99, 108]. While Sp100 also 
contributes to the repression of HSV-1 ICP0 gene expression [68, 69, 72], the influence of 
Sp100 on the epigenetic regulation of viral chromatin remains to be determined. Thus, rapid 
chromatinization and epigenetic modification of vDNA upon nuclear entry can restrict the 
initiation of productive HSV-1 infection. Importantly, this intrinsic host response to vDNA 
nuclear entry occurs prior to the activation of cytokine-mediated innate immune defences 
under low genome copy-numbers of infection (see below) [16, 112]. 
Expression of ICP0 induces the degradation and dispersal of PML-NB associated 
proteins from vDNA (see section 3) [16, 70, 113], which leads to a reduction in histone H3 
loading and enhanced levels of histone H3 acetylation on vDNA to promote transcription [70, 
96, 108, 114]. ICP0 also induces the degradation of ATRX and IFI16 [115-119]. However, 
the turnover of these proteins occurs with delayed kinetics relative to that of PML 
degradation [115, 118]. Such observations are likely to reflect the sequential degradation of 
host factors as infection progresses [120], a conclusion consistent with the differential 
accumulation of cellular factors on vDNA throughout the initiating cycle of HSV-1 infection 
[66, 121]. Indeed, recent microscopy studies have identified the histone H3.3 chaperone 
protein HIRA to restrict HSV-1 infection following the onset of vDNA replication, a host 
response antagonized by ICP0 through the nuclear dispersal of HIRA [73]. Thus, multiple 
histone H3.3 chaperone proteins (Daxx/ATRX and HIRA) can restrict the progress of HSV-1 
ICP0 replication at independent phases of infection. 
ICP0 has also been reported to bind CoREST, a component protein of the 
REST/CoREST/HDAC1,2/LSD1 nuclear repressor complex (Figure 2, residues 668-718; 
[122, 123]). ICP0 disrupts HDAC1 binding to CoREST, leading to HDAC1 translocation to 
the cytoplasm [122]. This ICP0-mediated action is proposed to block viral chromatin histone 
deacetylation and thus maintain a transcriptionally active state [114, 123, 124]. However, 
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complementation assays have shown ICP0-CoREST binding mutants to have only a modest 
impact on the acetylation status of viral chromatin relative to that of a functionally active 
RING-finger domain [114]. Of interest, the proposed CoREST binding site lies in a region of 
C-terminal homology conserved between primate ICP0 orthologues [84], which plays a multi-
functional role in the biological properties of ICP0, including USP7 binding and PML-NB 
localization (Figure 2) [72, 84]. Thus, while ICP0 has the potential to influence the epigenetic 
modification of viral chromatin in a RING-finger independent manner, the general consensus 
is that ICP0’s Ub ligase activity plays a central role in its ability to transactivate viral gene 
expression to stimulate the progression of infection. 
 
5. ICP0 modulation of the cellular DNA Damage Response (DDR) pathway 
Like many DNA viruses, HSV-1 shows an intimate relationship with the DDR pathway which 
can both positively and negatively influence the outcome of infection [125-128]. Upon 
nuclear infection, HSV-1 induces cellular DNA double strand breaks (DSBs) that are sensed 
by the MRN complex (MRE11, RAD50, and NBS1) which activates ATM leading to the 
phosphorylation of histones H2A and H2AX (γH2AX) flanking the chromatin break [129]. 
This stimulates the recruitment of MDC1, that recruits the cellular Ub ligases RNF8 and 
RNF168 to DSBs which ubiquitinate H2A and γH2AX, a signal that promotes the recruitment 
of downstream repair proteins [130, 131]. ICP0 targets RNF8 and RNF168 for degradation in 
a FHA-domain and phosphorylation-dependent manner, abrogating H2A and H2AX 
ubiquitination that restricts the recruitment of host DDR repair factors (e.g. TP53BP1) [39, 
40]. During HSV-1 ICP0 mutant infection, recruitment of these DDR proteins occurs in 
close proximity to vDNA in a PML and Sp100 independent manner [132]. Depletion of RNF8 
and RNF168 partially relieves the replication defect of an HSV-1 ICP0 mutant, 
demonstrating that RNF8 and RNF168 contribute to the intrinsic antiviral restriction of HSV-1 
through a mechanism antagonized by the Ub ligase activity of ICP0. Notably, SUMOylation 
is also known to play a key role in mediating the recruitment of DDR proteins to DSBs 
through SUMO-SIM interactions catalysed by PIAS SUMO ligases [133, 134]. Thus, it is 
likely that ICP0 utilizes SUMO-dependent and -independent targeting strategies to modulate 
the DDR during HSV-1 infection [89, 90].  
DSBs can also be sensed by Ku70/Ku80, leading to the recruitment of DNA-PK 
which promotes non-homologous end joining (NHEJ) at DSBs. ICP0 has been shown to 
induce the degradation of the catalytic subunit of DNA-PK (DNA-PKcs/PRKDC; [135, 136]). 
While it is clear that DNA-PKcs contributes to the cellular restriction of an HSV-1 ICP0 
mutant, the precise mechanism of restriction remains to be defined but has been linked to 
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viral genome circularization and regulation of innate immune defences (see below) [137, 
138]. 
ICP0 also localizes to centromeres where it induces the degradation of CENP-A, CENP-
B and, CENP-C [139-141], leading to cell cycle arrest and induction of an interphase 
Centromere Damage Response (iCDR) [142]. ICP0 has also been shown to promote 
remodelling of telomeres through the degradation of TPP1, leading to TERRA activation and 
enhanced levels of HSV-1 replication [143]. Thus, ICP0’s Ub ligase activity significantly 
remodels the intracellular chromatin environment to promote the progression of HSV-1 
infection. 
 
6. ICP0 scrambles innate immune pathways 
Detection of viral nucleic acid by host pattern recognition receptors (PRRs) plays a critical 
role in the activation of signalling cascades that lead to the production of pro-inflammatory 
cytokines, including type-I, II, and III IFNs [144-146]. Secretion of IFNs leads to the induction 
of hundreds of IFN stimulated genes (ISGs) that generate a cellular antiviral state that limits 
virus propagation and spread. HSV-1 ICP0 mutants are hypersensitive to IFN [10, 147-
149], highlighting a role for ICP0 in the regulation of innate immune defences to HSV-1 
infection. ICP0 contributes to nuclear PRR inactivation through the degradation of IFI16 and 
DNA-PKcs, which signal through STING-dependent and -independent pathways, 
respectively [103, 116-118, 138, 150]. Under low MOI conditions vDNA entry into the 
nucleus alone is not sufficient to trigger PRR activation leading to IFN and ISG expression, 
which has been shown to require the onset of vDNA replication [16]. PRR sensing by IFI16 
during HSV-1 ICP0 infection correlates with IFI16 forming nuclear filaments on vDNA in 
association with PML following the saturation of PML-NBs under high genome loads [16, 
118, 120]. Such observations highlight a clear segregation in the regulation of intrinsic and 
innate immune defences that concurrently restrict the initiation and propagation of HSV-1, 
respectively [16, 70, 112]. The relative spatiotemporal kinetics of IFI16 and DNA-PKcs PRR 
sensing of vDNA remains to be determined. Notably, PML isoforms II and IV have been 
shown to facilitate the loading of transcription factors (including IRF3, NF-B, and STAT1) 
onto cellular gene promoters that directly influence the induction of cytokines and ISG 
expression that contribute to the IFN hypersensitivity of HSV-1 ICP0 mutants [73, 151-153]. 
Thus, ICP0 inactivates intrinsic and innate immune defences early in the infectious cycle 
through the degradation of PML and cellular PRRs. ICP0 has also been reported to influence 
the regulation of NF-B signalling cascades [154-156]. However, the spatiotemporal 
regulation of this important signalling pathway under physiological infection conditions 
remains to be fully defined. It also remains to be determined as to what extent ICP0 
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reshapes the intracellular proteome upon infection of cytokine stimulated cells which express 
a full complement of ISG products. 
7. ICP0 and HSV-1 latency 
While significant progress has been made in defining the biochemical properties and cellular 
substrates of ICP0 during HSV-1 lytic infection (Figure 3), significantly less is known about 
the Ub ligase activity of ICP0 during viral reactivation from latency. Following primary 
infection, HSV-1 infects the neuronal dendrites of sensory ganglia that innervate infected 
tissues. Retrograde transport carries viral capsids along neuronal axons to the nucleus, 
wherein the viral genome undergoes epigenetic silencing leading to the establishment of 
latency (for detailed reviews see [157-160]). With respect to ICP0, animal models have 
shown ICP0 to be dispensable for the establishment and maintenance of HSV-1 latency, but 
to play a critical role during viral reactivation leading to de novo virus production [11, 12, 14, 
15]. This process occurs in an ICP0 RING-finger and phosphorylation dependent manner 
[14, 27, 49, 161], highlighting the importance of cellular ubiquitin machinery and kinases in 
the successful reactivation of HSV-1 from latency. Latent viral genomes can be observed to 
colocalize at distinct neuronal cell body sub-structures, including de novo assembled PML-
NBs and centromeres [107, 111, 162], known substrates of ICP0 in mitotic cells (Figure 3). 
While it’s tempting to speculate that ICP0 is required to disrupt these nuclear sub-domains 
that may otherwise promote or maintain vDNA in a state of transcriptional quiescence [107], 
a number of key observations have been reported that remain to be resolved. Firstly, low 
levels of ICP0 transcription have been detected in latently infected neurones [163, 164], 
although it remains to be determined if ICP0 is expressed or functionally active as a Ub 
ligase during latency. Secondly, viral reactivation is known to occur in distinct phases; 
widespread reanimation of non-canonical patterns of gene expression independently of viral 
protein synthesis (phase-1), followed by sequential patterns of canonical gene expression 
driven by the transactivating protein VP16 (phase-2) [165]. ICP0 is required for phase-2 
reactivation in a VP16-dependent manner [14, 166]. These data indicate that phase-1 
reanimation of viral transcription occurs independently of ICP0, a process that has been 
linked to neuronal stress and DDR pathways [167-169]. Collectively, these observations 
raise the possibility that ICP0 may have neuronal specific functions or spatiotemporal 
activities out with of those identified during the initiation of lytic infection in mitotic cells. With 
the advent of modern cytology techniques that enable the explant or differentiation of 
neurones in vitro [101, 170-174], the molecular function of ICP0 as a viral Ub ligase in 
modulating neuronal-specific processes, including host immune defences, epigenetic 
regulation, and the DDR, during HSV-1 latency and reactivation can now be addressed in 
detail. 
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8. Future Directions: Identification of new ICP0 substrates and host responses to 
viral infection  
While it is clear that the Ub ligase activity of ICP0 plays a central role in the infectious cycle 
of HSV-1, the full repertoire of ICP0 substrates remains poorly defined. With the 
development of modern proteomic and bioinformatic methodologies, it is now possible to 
quantify the impact of ICP0 ubiquitination on both host and viral proteomes. The 
development of an antibody that recognizes peptides modified by Ub has heralded a 
significant advancement in the ability to detect, isolate, and quantify ubiquitinated substrates 
on a proteome-wide scale by mass spectrometry [175, 176]. Upon trypsin digestion, Ub is 
cleaved leaving its C-terminal di-glycine bound to K residues in the modified substrate. This 
di-glycine remnant can be enriched by antibody affinity capture and analyzed by mass 
spectrometry to identify changes in the cellular ubiquitinome between sample populations. 
Comparison of WT to ICP0 RING-finger or ICP0 mutant HSV-1 infected cells over time 
would provide quantitative changes in host and viral ubiquitinomes through different phases 
of infection. Di-glycine remnant profiling in combination with whole cell proteomics would 
enable the identification of concomitant changes in protein abundance to that of 
ubiquitination status, enabling the identification of novel ICP0 substrates, new interfaces of 
viral host interaction, and fundamental insights into cellular functions of ubiquitination in 
response to virus infection. We hypothesize that ICP0 will target a variety of substrates for 
ubiquitination that will have proteasome-dependent and -independent functions. Conversely, 
we hypothesize the host cells will utilize ubiquitination to promote the activation of host 
immune defences that lead to the cellular restriction of HSV-1 in the absence of ICP0. The 
application of such proteomic methodologies will significantly advance our understanding of 
the requirements for ICP0 to remodel the cellular proteome under a range of conditions 
pertinent to HSV-1 infection; including cell type (e.g. epithelial vs. neuronal origin) and 
immunological status (e.g. resting vs. cytokine stimulated). Such studies will likely reveal 
new and important insights into cellular processes and host factors that mediate the 
spatiotemporal regulation of immune defences to HSV-1 infection. 
 
Conclusion 
ICP0 hijacks Ub machinery to disrupt cellular pathways that play important roles in the 
regulation of host immunity and cellular homeostasis, which to date includes the regulation 
of PML-NBs and host SUMOylation, epigenetic modification, DDR, and the cell cycle 
(summarized in figure 3). The outcome of this proteome remodelling creates a favourable 
environment to promote the onset of HSV-1 lytic replication, propagation, and productive 
reactivation of viral genomes from latency. As such, the identification and development of 
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small molecule inhibitors to ICP0 would provide significant therapeutic application in the 
treatment of recurrent HSV-1 infections by complementing host immune defences to block 
viral reactivation from latency. 
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Figure legends 
Figure 1. The RING-finger domain of ICP0 is conserved between α-herpesvirus 
orthologues. A) Alignment of α-herpesvirus (α-HV) ICP0 RING finger domains. Amino acid 
(aa) residues coordinating the two zinc cations (Zn2+) are highlighted in grey. Regions of 
secondary structure are underlined with horizontal dashes. B) Maximum likelihood 
phylogeny of the α-herpesvirus RING domain generated using RAxML with the LG amino 
acid substitution model. The phylogeny is rooted in the middle of the tree (mid-point rooted) 
and support for the relationships are shown at the nodes of the phylogeny using bootstrap. 
Only nodes with bootstrap support above 70% are shown. Abbreviation (common name), 
virus name, protein accession number, RING domain region: HHV1 (HSV-1), Human α-HV 
1, YP_009137074.1, 113:167; PanHV3, Chimpanzee herpesvirus strain 105640, 
YP_009010986.1, 121:175; HHV2 (HSV-2), Human α-HV 2, YP_009137210.1, 123:176; 
PaHV2, Papiine α-HV 2, YP_443846.2, 79:133; LeHV4, Leporid α-HV 4, YP_009230192.1, 
73:127; CeHV2, Cercopithecine α-HV 2, YP_164442.2, 86:140; McHV1, Macacine α-HV 1, 
NP_851859.2, 77:131; SaHV1, Saimiriine α-HV 1, YP_003933840.1, 196:250; AtHV1, 
Ateline α-HV 1, YP_009361938.1, 196:250; SuHV1, Suid α-HV 1, YP_068377.2, 1:52; 
MaHV1, Macropodid α-HV 1, YP_009227214.1, 57:111; FeHV1, Felid α-HV 1, 
YP_003331582.1, 5:57; BoHV1, Bovine α-HV 1, NP_045363.1, 10:62; BoHV5, Bovine α-HV 
5, NP_954951.1, 18:70; BuHV1, Bubaline α-HV 1, YP_0096646811, 17:69; CvHV2, Cervid 
α-HV 2, AVT50781.1, 25:77; CvHV3, Cervid α-HV 3, AVT50645.1, 10:62; CvHV1, Cervid α-
HV 1, AVT50711.1, 10:62; PRV, Pseudorabies virus Ea, AAG17904.1, 43:95; MoAHV1, 
Beluga whale α-HV 1, ASW27104.1, 27:79; EHV3, Equid α-HV 3, YP_009054966.1, 5:57; 
CeHV9, Cercopithecine α-HV 9, NP_077475.1, 16:68; CaHV1, Canid α-HV 1, 
YP_009252287.1, 5:57; EHV4, Equid α-HV 4, NP_045280.1, 6:58; EHV1, Equid α-HV 1, 
YP_053107.1, 5:57; HHV3 (VZV), Human α-HV 3, NP_040183.1, 16:68; SpAHV1, Sphenicid 
α-HV 1, YP_009342410.1, 62:126; EHV8, Equid α-HV 8, YP_006273043.1 ,5:58. 
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Figure 2. ICP0 RING-finger dependent and independent interactions. Schematic 
representation of the ICP0 ORF amino acid (aa) residues 1-775. Spliced exons (Ex): Ex1, aa 
1-19; Ex2, aa 20-241; Ex3, aa 242-775. Ex2 harbours the RING finger domain (black box, aa 
116-156) influencing ICP0 oligomerization together with aa 633-771 (highlighted yellow; [45, 
177, 178]). ICP0 RING-finger residues required for UBE2D1 interaction (highlighted fuchsia 
[27]). ICP0 phosphorylation motifs are indicated with grey pins: FHA domain (pS64 and 67-
pTELF-70; [40]) recruit CK1 (lilac rhombus), FOXK2, and DDR proteins RNF8, CHK2 and 
NBS1 (highlighted blue; [40]). ICP0 phosphorylation regions Phos1 (S224, T226, T231, 
T232); Phos2 (S365, S367, S371), and Phos3 (S508, S514, S517, T518) [179]. SLSs 1-7 
(aa 164-167, 176-179, 331-334, 362-363, 651-654, 664-667 and 678-681, respectively) are 
indicated with black vertical half-moons [81]; SLS4 and aa 634-719 influence PML-NB 
localization (highlighted grey; [84]). SIAH binding motif (aa 401-410; [180]), a NLS (aa 500-
506), and USP7 binding motif (aa 620-624) are indicated with vertical rectangles. ICP0 
regions of SUMO2/3 (aa 241-388, highlighted orange) and SUMO1 (aa 594-775, highlighted 
red) binding shown [81, 84]. CoREST interaction region (aa 668-718, highlighted green; 
[123]). Jo
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Figure 3. ICP0 interacts with a wide variety of overlapping host pathways. Protein 
interaction network of host proteins reported to associate with (grey inner circles) or to be 
degraded (brown inner circles) by ICP0 during HSV-1 infection. Proteins identified by manual 
curation of the literature. Interaction network and functional analysis was generated using 
STRING (high confidence threshold, 0.7). Pathway annotations based on the Reactome 
database. Proteins enriched in the top 6 pathways are coloured (Outer circle, as indicated). 
Proteins that show interconnectivity are highlighted by grey lines. 
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